Core Insights - Anaveon is a Swiss biotech company focused on developing IL-2 receptor agonists to enhance cancer immunotherapy by selectively activating CD8+ T cells and NK cells while inhibiting Treg cell activity [2][6] - The company was founded in 2017 as a spin-off from the University of Zurich by Andreas Katopodis and Onur Boyman, both of whom have extensive experience in immunology and drug development [2][8] Company Overview - Anaveon has developed a lead pipeline candidate, ANV600, which is a novel bispecific compound combining an IL-2Rβ/γ selective agonist with a non-blocking PD-1 targeting antibody [7] - The company is currently conducting an open-label Phase 1/2 clinical trial for ANV600 to evaluate its safety and anti-tumor activity in patients with relapsed or refractory advanced solid tumors [7] Product Development - Anaveon's IL-2 receptor agonist is engineered to selectively activate the IL-2Rβ/γ signaling pathway, enhancing the immune response while minimizing off-target effects [6][7] - Another pipeline candidate, ANV700, combines a non-blocking PD-1 targeting antibody with IL-21 PAC to increase the cytotoxicity of CD8+ T cells in the tumor microenvironment [7] Funding and Recognition - Anaveon completed a Series A financing round of CHF 35 million in 2019, led by Syncona, and a Series B financing round of CHF 110 million in 2021, led by Forbion, with participation from Cowen Healthcare Investments, Pfizer Ventures, and Pontifax [8] - The company was recognized in the 2022 TOP100 Swiss Startups list, highlighting its innovative potential and market prospects in the biotech sector [10]